Trivaris FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (Discontinued) (First approved June 16, 2008)
Brand name: Trivaris
Generic name: triamcinolone acetonide
Dosage form: Intravitreal Injection
Company: Allergan plc
Treatment for: Ocular Inflammatory Conditions
Marketing Status: Discontinued
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Development timeline for Trivaris
| Date | Article |
|---|---|
| Jun 17, 2008 | Approval Allergan Receives U.S. Food and Drug Administration Approval for Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
